Diabetes drug approved to treat heart failure

Forxiga (dapagliflozin) is the first SGLT2 inhibitor licensed for the treatment of heart failure.

by Chloe Harman
Forxiga (dapagliflozin) is a new treatment option for patients with heart failure. | GETTY IMAGES
Forxiga (dapagliflozin) is a new treatment option for patients with heart failure. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package